GlassScriptPhysician profile
Mark G Ballif
NPI 1376522573
$5,696.14
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $202 · 2021: $294 · 2022: $3,313 · 2023: $356 · 2024: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.83 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,156.71 | 2021-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $923.15 | 2019-2024 | Veritas Vision System |
| Alcon Vision LLC | $504.38 | 2019-2024 | Hydrus Microstent, Clareon, Centurion |
| Allergan, INC. | $201.79 | 2019-2021 | |
| Glaukos Corporation | $168.24 | 2021-2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Iaccess Precision Blade |
| Novartis Pharmaceuticals Corporation | $137.51 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $131.73 | 2023-2024 | Stellaris, Vyzulta, Miebo |
| Abbvie INC. | $130.31 | 2022-2024 | Vuity, Lumigan |
| Sun Pharmaceutical Industries INC. | $102.28 | 2019 | |
| Dompe US, INC. | $42.86 | 2020-2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Eyepoint US, INC. | $27.15 | 2020 | |
| Shire North American Group INC | $21.75 | 2019 | |
| Oyster Point Pharma, INC. | $20.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.85 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18.71 | 2021 | |
| Alimera Sciences, INC. | $15.51 | 2021 | |
| Sight Sciences, INC. | $11.75 | 2021 | |
| Horizon Therapeutics Plc | $11.62 | 2021 | |
| Genentech, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ballif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.